MICA develops an AI decision support system that enhances mammography analysis by accurately diagnosing suspicious findings in breast tissue, particularly in dense breasts. This technology addresses the issue of outdated detection methods that lead to errors, enabling earlier and more effective treatment for breast cancer.
Funding
$3.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Mammography analysis relies on manual interpretation, which can lead to errors and inaccurate detection, particularly in women with dense breasts, making early and effective breast cancer treatment challenging. Outdated detection methods contribute to delayed diagnoses and potentially poorer patient outcomes.
Solution
MICA offers an AI-powered decision support system designed to enhance the precision and efficacy of mammography analysis. By leveraging millions of image scans, MICA's system identifies suspicious findings in breast tissue, including dense breasts, potentially before a tumor fully develops. The AI supports radiologists in their analysis, facilitating more personalized and timely treatment plans for patients.
Target Audience
The primary target audience includes radiologists and hospitals seeking to improve the accuracy and efficiency of breast cancer detection through advanced AI-driven analysis.
Features
- AI-driven analysis of mammograms for both normal and dense breasts (CESM)
- Comparison of mammograms across different time periods to identify subtle changes
- Integration of millions of image scans to improve diagnostic accuracy
- Support for personalized treatment decisions based on AI-enhanced analysis